Bernstein analyst William Pickering raised the firm’s price target on Biogen (BIIB) to $201 from $191 and keeps a Market Perform rating on the shares. The firm notes Biogen delivered a solid set of numbers to cap FY25, beating consensus by 3% on revenue and 17% on EPS. More importantly, the FY26 guide is a bit better than consensus on the bottom line, with Biogen guiding EPS up 3% despite revenue guided down mid-single-digit.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $228 from $194 at H.C. Wainwright
- Biogen: Undervalued Cash Flows and Growing Leqembi Franchise Support Raised Price Target and Buy Rating
- Biogen price target raised to $200 from $190 at Wells Fargo
- Biogen price target raised to $207 from $189 at BofA
- Biogen price target raised to $190 from $156 at Morgan Stanley